Ocular Therapeutix Participates in Upcoming Scientific Conferences
ByAinvest
Tuesday, Jul 22, 2025 7:02 am ET1min read
AMD--
Ocular Therapeutix will be showcasing its research and innovations at the OIS Retina 2025 conference, the ASRS 2025 conference, and the Women in Ophthalmology (WIO 2025) conference. These conferences provide a platform for the company to engage with fellow researchers, clinicians, and industry professionals, sharing the latest advancements in retinal disease treatment and drug delivery technologies.
The company's investigational product candidate, AXPAXLI, is designed to address the unmet needs in wet AMD treatment. AXPAXLI is currently being evaluated in a phase 3 clinical trial, SOL-R, which aims to assess the safety and efficacy of the drug in patients with wet AMD. The trial, which recently completed enrollment, will evaluate AXPAXLI in at least 555 patients in a multi-center, double-masked, randomized (2:2:1), 3-arm study [3].
Ocular Therapeutix's participation in these conferences is part of its ongoing commitment to advancing the field of ophthalmology and improving patient outcomes. The company's focus on innovation and collaboration is reflected in its involvement in key scientific events and its dedication to developing novel treatment options for retinal diseases.
References:
[1] https://www.ophthalmologytimes.com/clinical/amd
[2] https://www.ophthalmologytimes.com/clinical/amd
[3] https://www.ophthalmologytimes.com/clinical/amd
OCUL--
Ocular Therapeutix to participate in upcoming scientific conferences in July and August 2025, including OIS Retina 2025, ASRS 2025, and Women in Ophthalmology (WIO 2025). The company will present on various topics related to drug delivery and retinal disease, including its investigational product candidate AXPAXLI for wet age-related macular degeneration.
Ocular Therapeutix, a leading innovator in retinal disease treatment, has announced its participation in several upcoming scientific conferences in July and August 2025. The company will be presenting on various topics related to drug delivery and retinal disease, including its investigational product candidate AXPAXLI for wet age-related macular degeneration (AMD).Ocular Therapeutix will be showcasing its research and innovations at the OIS Retina 2025 conference, the ASRS 2025 conference, and the Women in Ophthalmology (WIO 2025) conference. These conferences provide a platform for the company to engage with fellow researchers, clinicians, and industry professionals, sharing the latest advancements in retinal disease treatment and drug delivery technologies.
The company's investigational product candidate, AXPAXLI, is designed to address the unmet needs in wet AMD treatment. AXPAXLI is currently being evaluated in a phase 3 clinical trial, SOL-R, which aims to assess the safety and efficacy of the drug in patients with wet AMD. The trial, which recently completed enrollment, will evaluate AXPAXLI in at least 555 patients in a multi-center, double-masked, randomized (2:2:1), 3-arm study [3].
Ocular Therapeutix's participation in these conferences is part of its ongoing commitment to advancing the field of ophthalmology and improving patient outcomes. The company's focus on innovation and collaboration is reflected in its involvement in key scientific events and its dedication to developing novel treatment options for retinal diseases.
References:
[1] https://www.ophthalmologytimes.com/clinical/amd
[2] https://www.ophthalmologytimes.com/clinical/amd
[3] https://www.ophthalmologytimes.com/clinical/amd
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet